my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
26-01-2012: Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.
The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.
“We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies,” said Dr. Bertil Lindmark, CSO, Executive Director R&D of Almirall.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Almirall and BioFocus enter research alliance
Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFo ... more
Almirall enters into Integrated Discovery Agreement with Proteros
Almirall, S.A. and Proteros biostructures GmbH announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.Under the agreement Proteros will apply its protein structure-based drug ... more
Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Basilea Pharmaceutica Ltd. announces that it has received a milestone payment of EUR 5.5 million under its distribution agreement for Toctino® (alitretinoin) with Almirall, S.A. The milestone payment of EUR 5.5 million relates to Italy where Toctino® will become available in the coming week ... more
Almirall is a consolidated international pharmaceutical company where we research, develop and commercialise own R&D and licensed specialities with the aim of improving the health and quality of life of human beings. We devote the maximum human and economic resources to constant research i ... more
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads an ... more
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of th ... more
Almirall and BioFocus enter research alliance
Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFo ... more
As the service division of Galapagos, BioFocus DPI offers a full suite of target-to-drug discovery products and services. Our aim is to expand our partners’ drug pipeline by accelerating the gene-to-candidate discovery process. We achieve this by offering a biologically-focused discovery ... more
We are a genomics based drug discovery company, that has drug discovery programs based on proprietary disease modifying drug targets. Our vision is to bring novel drugs to the market in selected diseases areas for which there is a need for effective and safe medicines. We focus on developin ... more
Galapagos acquires Cangenix, a structure-based drug discovery company
Galapagos NV (GLPG) and Cangenix Ltd announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering. Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 pot ... more
Galapagos discovers novel class of antibiotics
Galapagos NV announced that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.Bacterial infections that ... more
Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads an ... more
Galapagos is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery an ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
